Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ADAG
ADAG logo

ADAG Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Adagene Inc (ADAG) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
3.980
1 Day change
3.65%
52 Week Range
4.750
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Adagene Inc (ADAG) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has shown strong recent price momentum, bullish technical indicators, and a significant upside potential based on analyst target prices. Despite the absence of proprietary trading signals, the stock's current trajectory and favorable analyst sentiment make it a compelling investment opportunity.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 71.954, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock has broken through key resistance levels, with the next resistance at 4.094. Overall, technical indicators suggest a strong upward trend.

Positive Catalysts

  • Guggenheim raised the price target to $10, maintaining a Buy rating.

  • Analysts project a 166.29% upside based on the average target price of $9.

  • Strong price momentum with an 11.61% regular market gain and a 2.02% post-market gain.

Neutral/Negative Catalysts

  • No significant hedge fund or insider trading activity.

  • Congress trading data is unavailable, limiting visibility into political sentiment.

Financial Performance

Financial data is unavailable for the latest quarter, so growth trends cannot be assessed.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish, with Guggenheim raising the price target to $10 and maintaining a Buy rating. The average analyst target price of $9.40 suggests a significant upside potential of 166.29%.

Wall Street analysts forecast ADAG stock price to rise
2 Analyst Rating
Wall Street analysts forecast ADAG stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.840
sliders
Low
8
Averages
8.5
High
9
Current: 3.840
sliders
Low
8
Averages
8.5
High
9
Guggenheim
Buy
maintain
$9 -> $10
AI Analysis
2026-04-06
Reason
Guggenheim
Price Target
$9 -> $10
AI Analysis
2026-04-06
maintain
Buy
Reason
Guggenheim raised the firm's price target on Adagene to $10 from $9 and keeps a Buy rating on the shares. The firm is updating its model for FY25 earnings, the ATM offering, and modest adjustments to its assumptions for lead asset muzastotug.
Guggenheim
initiated
$9
2025-11-24
Reason
Guggenheim
Price Target
$9
2025-11-24
initiated
Reason
As previously reported, Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target. The company's lead product candidate muzastotug is currently in Phase 2 for patients with late-line microsatellite stable colorectal cancer without liver metastases, notes the analyst. The company has reported "compelling" Phase 1 data for muzastotug plus pembrolizumab that exceed current standard of care benchmarks in third-line and later CRC, according to the analyst, who calls this "an area of significant unmet need."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ADAG
Unlock Now

People Also Watch